W Kruis

Summary

Affiliation: Evangelisches Krankenhaus Kalk
Country: Germany

Publications

  1. ncbi request reprint [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?]
    B Lanyi
    Abteilung fur Innere Medizin, Gastroenterologie, Evangelisches Krankenhaus Köln Kalk
    Dtsch Med Wochenschr 130:1944-7. 2005
  2. ncbi request reprint [Diagnosis of functional bowel diseases]
    W Kruis
    Innere Abteilung, Evangelisches Krankenhaus Kalk, Universitat zu Koln
    Praxis (Bern 1994) 96:319-22. 2007
  3. ncbi request reprint Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis
    Wolfgang Kruis
    Evangelisches Krankenhaus Kalk, Innere Abteilung, Universitat zu Koln, Germany
    World J Gastroenterol 11:7001-6. 2005
  4. pmc Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Gut 53:1617-23. 2004
  5. ncbi request reprint Review article: antibiotics and probiotics in inflammatory bowel disease
    W Kruis
    Evangelisches Krankenhaus Kalk, Teaching Hospital for the University of Cologne, Germany
    Aliment Pharmacol Ther 20:75-8. 2004
  6. ncbi request reprint [Inflammatory bowel diseases]
    W Kruis
    Evangelisches Krankenhaus Kalk, Innere Abteilung
    Dtsch Med Wochenschr 129:S73-5. 2004
  7. ncbi request reprint [Crohn's disease--standards of treatment 2004]
    W Kruis
    Evangelisches Krankenhaus Kalk, Akademisches Lehrkrankenhaus für die Universität zu Köln
    Praxis (Bern 1994) 94:1595-8. 2005
  8. doi request reprint Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease
    G Terheggen
    Department of Internal Medicine, Evangelisches Krankenhaus Kalk, Koln, Germany
    Endoscopy 40:656-63. 2008
  9. pmc Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
    Gut 58:233-40. 2009
  10. doi request reprint [Modern therapy of diverticular disease]
    L Leifeld
    Abteilung fur Innere Medizin, Evangelisches Krankenhaus Kalk, Koln, Deutschland
    Internist (Berl) 49:1415-6, 1418-20. 2008

Detail Information

Publications34

  1. ncbi request reprint [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?]
    B Lanyi
    Abteilung fur Innere Medizin, Gastroenterologie, Evangelisches Krankenhaus Köln Kalk
    Dtsch Med Wochenschr 130:1944-7. 2005
    ..7 months earlier active (Crohn's) ileocolitis had been diagnosed. She had received several bouts of steroids and had been in clinical remission for 12 weeks under a dosage of 40 mg/d prednisone...
  2. ncbi request reprint [Diagnosis of functional bowel diseases]
    W Kruis
    Innere Abteilung, Evangelisches Krankenhaus Kalk, Universitat zu Koln
    Praxis (Bern 1994) 96:319-22. 2007
    ..History either confirms a positive diagnosis or initiates some complementary investigations. Redundant and dangerous technical procedures should be avoided in the diagnostic work up...
  3. ncbi request reprint Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis
    Wolfgang Kruis
    Evangelisches Krankenhaus Kalk, Innere Abteilung, Universitat zu Koln, Germany
    World J Gastroenterol 11:7001-6. 2005
    ..To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy...
  4. pmc Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Gut 53:1617-23. 2004
    ..We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis...
  5. ncbi request reprint Review article: antibiotics and probiotics in inflammatory bowel disease
    W Kruis
    Evangelisches Krankenhaus Kalk, Teaching Hospital for the University of Cologne, Germany
    Aliment Pharmacol Ther 20:75-8. 2004
    ..Further investigations may detect additional clinically effective probiotics and other clinical indications...
  6. ncbi request reprint [Inflammatory bowel diseases]
    W Kruis
    Evangelisches Krankenhaus Kalk, Innere Abteilung
    Dtsch Med Wochenschr 129:S73-5. 2004
  7. ncbi request reprint [Crohn's disease--standards of treatment 2004]
    W Kruis
    Evangelisches Krankenhaus Kalk, Akademisches Lehrkrankenhaus für die Universität zu Köln
    Praxis (Bern 1994) 94:1595-8. 2005
    ..Maintenance of remission should not be done on a regular basis but rather regarding the individual patients' situation. Risks have to be carefully balanced with possible benefits. The most important aim of treatment is quality of life...
  8. doi request reprint Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease
    G Terheggen
    Department of Internal Medicine, Evangelisches Krankenhaus Kalk, Koln, Germany
    Endoscopy 40:656-63. 2008
    ..The aim of this study was to assess prospectively the risks of ileocolonoscopy in relation to various disease patterns and to compare possible burdens of the procedure in the endoscopist's and the patient's perception...
  9. pmc Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
    Gut 58:233-40. 2009
    ..To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis...
  10. doi request reprint [Modern therapy of diverticular disease]
    L Leifeld
    Abteilung fur Innere Medizin, Evangelisches Krankenhaus Kalk, Koln, Deutschland
    Internist (Berl) 49:1415-6, 1418-20. 2008
    ..A free perforation is still an absolute indication for emergency operation. In recurring diverticulitis indication for resection of the affected segment of the bowel should be considered depending on the extent of former attacks...
  11. doi request reprint Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Aliment Pharmacol Ther 33:313-22. 2011
    ..Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited...
  12. pmc Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses
    W Kruis
    Evangelisches Krankenhaus Kalk, Teaching Hospital of the University of Cologne, Germany
    Gut 49:783-9. 2001
    ..5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated...
  13. doi request reprint Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis
    L Leifeld
    Evangelisches Krankenhaus Kalk, Cologne, Germany
    Aliment Pharmacol Ther 34:1115-22. 2011
    ..Different oral formulations of 'mesalazine (mesalamine)' may have different efficacy in distal ulcerative colitis...
  14. ncbi request reprint Probiotics: do they help to control intestinal inflammation?
    S K Bohm
    Evangelisches Krankenhaus Kalk, Abteilung für Innere Medzin, Universitat zu Koln, Buchforststrasse 2, Koln, Germany
    Ann N Y Acad Sci 1072:339-50. 2006
    ..Further understanding of the complex molecular mechanisms leading to the effectiveness of probiotics will also spur the development of more successful probiotic formulations...
  15. ncbi request reprint [Future directions of German gastroenterology--personal notes on the occasion of the 60th annual meeting of the German Gastroenterological Association]
    W Kruis
    Innere Abteilung, Evangelisches Krankenhaus Kalk GmbH, Koln
    Z Gastroenterol 43:1281-4. 2005
  16. ncbi request reprint [Probiotics in chronic inflammatory bowel disease]
    S Bohm
    Evangelisches Krankenhaus Kalk, Koln
    MMW Fortschr Med 148:30-4. 2006
    ..These indications have since been incorporated in valid guidelines. Initial clinical studies have also provided promising results regarding the efficacy of VSL#3 in preventing pouchitis immediately following proctocolectomy...
  17. ncbi request reprint [Diverticulosis and diverticulitis]
    R M Hoffmann
    Medizinische Klinik I, Kreiskrankenhaus Gummersbach
    Internist (Berl) 46:671-83; quiz 684. 2005
    ..Treatment of diverticulitis and its complications requires careful consideration of conservative and surgical approaches and close interdisciplinary cooperation...
  18. doi request reprint [Diverticulitis should be treated conservatively]
    W Kruis
    Evangelisches Krankenhaus Kalk, Buchforststrasse 2, Koln
    Dtsch Med Wochenschr 133:1922. 2008
  19. doi request reprint Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study
    W Kruis
    Innere Abteilung Ev, Krankenhaus Kalk, University of Cologne, Koln, Germany
    Aliment Pharmacol Ther 37:680-90. 2013
    ..Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse...
  20. ncbi request reprint [Endoscopic ultrasound-guided fine-needle aspiration]
    S Schanz
    Abteilung fur Innere Medizin, Gastroenterologie, Evangelisches Krankenhaus Köln Kalk
    Dtsch Med Wochenschr 130:1957-61. 2005
  21. ncbi request reprint Addition of senna improves colonoscopy preparation with lavage: a prospective randomized trial
    D J Ziegenhagen
    Department of Medicine I, University of Cologne, Germany
    Gastrointest Endosc 37:547-9. 1991
    ..In the senna/PEG-ELS group, significantly less (p less than 0.05) lavage fluid was needed. We conclude that the combination of senna and PEG-ELS is more effective than PEG-ELS in cleansing the colon for colonoscopy...
  22. ncbi request reprint [Mysterious lower gastrointestinal bleeding in diverticular disease of the colon]
    G Vosskamp
    Innere Abteilung, Evangelisches Krankenhaus Köln Kalk
    Dtsch Med Wochenschr 130:1948-50. 2005
    ..At her admission to hospital she complained about general weakness and painless melena. Within the last few years the patient had been treated with aspirin and phenprocoumon for chronic atrial fibrillation and coronary heart disease...
  23. ncbi request reprint [Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility]
    R M Hoffmann
    Innere Abteilung, Evangelisches Krankenhaus Kalk, Koln
    Dtsch Med Wochenschr 130:1938-43. 2005
    ..We investigated the effect of 4-methyl-umbiliferone p. o. and i. v. on gall bladder and common bile duct motility and studied potentially indirect effects via alterations in bile acid metabolism...
  24. ncbi request reprint [Probiotics and prebiotics--a renaissance?]
    R M Hoffmann
    Innere Abteilung, Evangelisches Krankenhaus Kalk, Buchforststrasse 2, 51103 Köln
    Internist (Berl) 43:1400-6. 2002
  25. doi request reprint Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis
    W Kruis
    Evangelisches Krankenhaus Kalk, Innere Medizin, Koln, Germany
    J Crohns Colitis 7:e263-70. 2013
    ..Predictive factors for a mild course of Crohn's disease (CD) may have therapeutic consequences, but as yet have not been identified...
  26. ncbi request reprint [Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease]
    J C Hoffmann
    Medizinische Klinik I mit Schwerpunkt Gastroenterologie Infektiologie Rheumatologie, Charite, Universitatsmedizin Berlin
    Z Gastroenterol 42:979-83. 2004
  27. doi request reprint [Short version of the updated German S3 (level 3) guideline on diagnosis and treatment of Crohn's disease]
    J C Hoffmann
    Medizinische Klinik I, St Marienkrankenhaus Ludwigshafen
    Dtsch Med Wochenschr 133:1924-9. 2008
  28. ncbi request reprint [Ulcerative colitis. Maintenance therapy]
    W Kruis
    Abt Innere Medizin, Evangelisches Krankenhaus Köln Kalk
    Z Gastroenterol 42:1011-4. 2004
  29. ncbi request reprint [Interdisciplinarity in gastroenterology - a necessary and inevitable step forward]
    W Kruis
    Dtsch Med Wochenschr 130:1933. 2005
  30. ncbi request reprint [Determination of placebo effect in irritable bowel syndrome]
    P Enck
    Medizinische Klinik VI Psychosomatische Medizin und Psychotherapie, Universitatsklinikum Tubingen
    Dtsch Med Wochenschr 130:1934-7. 2005
    ..The determinants of the placebo effect are not well established. Goal of this study was to explore likely predictive factors in an already published data set...
  31. ncbi request reprint [From chronic inflammation to metastasizing colon cancer--the endless story of the NSAIDs]
    H Allgayer
    Schwerpunkt Verdauungs und Stoffwechselerkrankungen, Rehaklinik Ob der Tauber, Bad Mergentheim, Akademisches Lehrkrankenhaus der Universität Heidelberg
    Z Gastroenterol 44:611-3. 2006
  32. ncbi request reprint Rare extraintestinal manifestations of inflammatory bowel disease
    R M Hoffmann
    Ev Krankenhaus Kalk, Akad Lehrkrankenhaus der Universität zu Köln, Buchforststr 2 D 51103 Köln
    Inflamm Bowel Dis 10:140-7. 2004
  33. ncbi request reprint Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16
    M E Curran
    Axys Pharmaceuticals Inc, La Jolla, California, USA
    Gastroenterology 115:1066-71. 1998
    ..The significance of these linkages will be determined by studies in large patient collections. The aim of this study was to replicate IBD linkages on chromosomes 12 and 16 in a large European cohort...
  34. ncbi request reprint [Microscopic colitis]
    C Pohl
    Innere Abteilung, St Elisabeth Krankenhaus, Koln
    Dtsch Med Wochenschr 130:1962-7. 2005